Sandoz anticipates additional $3B in potential net sales over five years in pipeline expansion
Sandoz today gave insight into its overall strategy once it becomes an independent company later this year, including plans to expand its work in biosimilars and build revenue after claiming $9.1 billion in sales last year.
The generics maker and current Novartis division hosted a capital markets day in New York City on Thursday — the first of two such days, with the second one planned for London next week.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.